The legal battle was dropped in March after the pharmacy agreed to stop advertising the compounds and sell semaglutide under the Ozempic and Wegovy brand
Investors might be better served by taking a less focused approach toward investing in obesity stocks and consider a firm like Roche, where we like the overall portfolio and investors get some exposure to new obesity drug development, Conover says
These include bowel obstruction, chronic gallbladder disease, pancreatic cancer, liver failure, and other life-threatening diagnoses
Emerging consumer data show that individuals on GLP-1 therapies reduce their caloric intake significantly, often by 20% or more, and cut grocery spending by roughly 5% within months of starting treatment
Pete experienced no side effects with this fat burner and did not experience any unpleasant taste or aftertaste from these capsules, rating the flavor a 3 out of 5which we consider neutral
Caughey, B, editor